Literature DB >> 22956855

Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer.

Lu Wang1, Andrea Rotnitzky, Xihong Lin, Randall E Millikan, Peter F Thall.   

Abstract

We present new statistical analyses of data arising from a clinical trial designed to compare two-stage dynamic treatment regimes (DTRs) for advanced prostate cancer. The trial protocol mandated that patients were to be initially randomized among four chemotherapies, and that those who responded poorly were to be rerandomized to one of the remaining candidate therapies. The primary aim was to compare the DTRs' overall success rates, with success defined by the occurrence of successful responses in each of two consecutive courses of the patient's therapy. Of the one hundred and fifty study participants, forty seven did not complete their therapy per the algorithm. However, thirty five of them did so for reasons that precluded further chemotherapy; i.e. toxicity and/or progressive disease. Consequently, rather than comparing the overall success rates of the DTRs in the unrealistic event that these patients had remained on their assigned chemotherapies, we conducted an analysis that compared viable switch rules defined by the per-protocol rules but with the additional provision that patients who developed toxicity or progressive disease switch to a non-prespecified therapeutic or palliative strategy. This modification involved consideration of bivariate per-course outcomes encoding both efficacy and toxicity. We used numerical scores elicited from the trial's Principal Investigator to quantify the clinical desirability of each bivariate per-course outcome, and defined one endpoint as their average over all courses of treatment. Two other simpler sets of scores as well as log survival time also were used as endpoints. Estimation of each DTR-specific mean score was conducted using inverse probability weighted methods that assumed that missingness in the twelve remaining drop-outs was informative but explainable in that it only depended on past recorded data. We conducted additional worst-best case analyses to evaluate sensitivity of our findings to extreme departures from the explainable drop-out assumption.

Entities:  

Year:  2012        PMID: 22956855      PMCID: PMC3433243          DOI: 10.1080/01621459.2011.641416

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  15 in total

1.  Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials.

Authors:  Jared K Lunceford; Marie Davidian; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  An experimental design for the development of adaptive treatment strategies.

Authors:  S A Murphy
Journal:  Stat Med       Date:  2005-05-30       Impact factor: 2.373

3.  Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?

Authors:  Andrew J Armstrong; Mario Eisenberger
Journal:  Nat Clin Pract Urol       Date:  2006-05

4.  Statistical methods for analyzing sequentially randomized trials.

Authors:  Oliver Bembom; Mark J van der Laan
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

5.  Estimation and extrapolation of optimal treatment and testing strategies.

Authors:  James Robins; Liliana Orellana; Andrea Rotnitzky
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

6.  Analyzing sequentially randomized trials based on causal effect models for realistic individualized treatment rules.

Authors:  Oliver Bembom; Mark J van der Laan
Journal:  Stat Med       Date:  2008-08-30       Impact factor: 2.373

7.  Marginal Mean Models for Dynamic Regimes.

Authors:  S A Murphy; M J van der Laan; J M Robins
Journal:  J Am Stat Assoc       Date:  2001-12-01       Impact factor: 5.033

8.  Evaluating multiple treatment courses in clinical trials.

Authors:  P F Thall; R E Millikan; H G Sung
Journal:  Stat Med       Date:  2000-04-30       Impact factor: 2.373

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.

Authors:  Peter F Thall; Christopher Logothetis; Lance C Pagliaro; Sijin Wen; Melissa A Brown; Dallas Williams; Randall E Millikan
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

View more
  28 in total

1.  Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.

Authors:  P Thall; P Fox; J Wathen
Journal:  Ann Oncol       Date:  2015-05-15       Impact factor: 32.976

2.  Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research.

Authors:  Daniel Almirall; Inbal Nahum-Shani; Nancy E Sherwood; Susan A Murphy
Journal:  Transl Behav Med       Date:  2014-09       Impact factor: 3.046

3.  A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes.

Authors:  Thomas A Murray; Ying Yuan; Peter F Thall
Journal:  J Am Stat Assoc       Date:  2018-10-08       Impact factor: 5.033

4.  Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.

Authors:  Jincheng Shen; Lu Wang; Jeremy M G Taylor
Journal:  Biometrics       Date:  2016-11-28       Impact factor: 2.571

5.  Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer.

Authors:  Thomas A Murray; Peter F Thall; Ying Yuan; Sarah McAvoy; Daniel R Gomez
Journal:  J Am Stat Assoc       Date:  2017-05-03       Impact factor: 5.033

6.  Dynamic Treatment Regimes.

Authors:  Bibhas Chakraborty; Susan A Murphy
Journal:  Annu Rev Stat Appl       Date:  2014       Impact factor: 5.810

7.  Assessing Time-Varying Causal Effect Moderation in Mobile Health.

Authors:  Audrey Boruvka; Daniel Almirall; Katie Witkiewitz; Susan A Murphy
Journal:  J Am Stat Assoc       Date:  2017-03-29       Impact factor: 5.033

8.  Inference about the expected performance of a data-driven dynamic treatment regime.

Authors:  Bibhas Chakraborty; Eric B Laber; Ying-Qi Zhao
Journal:  Clin Trials       Date:  2014-06-12       Impact factor: 2.486

9.  Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials.

Authors:  Zhiguo Li
Journal:  Stat Med       Date:  2016-09-19       Impact factor: 2.373

10.  Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times.

Authors:  Yanxun Xu; Peter Müller; Abdus S Wahed; Peter F Thall
Journal:  J Am Stat Assoc       Date:  2016-10-18       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.